reports
Louisiana-Pacific Corp: 1 director
A director at Louisiana-Pacific Corp sold 28,332 shares at 87.435USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...
Avalo Therapeutics to Participate in Upcoming Investor Conferences
Avalo Therapeutics to Participate in Upcoming Investor Conferences WAYNE, Pa., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced that management will participate in the following investor conferences: Guggenheim Emerging Outlook: Biotech Summit 2026Fireside ChatFebruary 11, 2026, at 10:00 am ET Oppenheimer 36th Annual Healthcare Life Sciences ConferenceFireside ChatFebruary 25, 2026, at 10:00 am ET Live webcasts ...
American Assets Trust, Inc. Reports Fourth Quarter and Year End 2025 F...
American Assets Trust, Inc. Reports Fourth Quarter and Year End 2025 Financial Results SAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- American Assets Trust, Inc. (NYSE: AAT) (the “company”) today reported financial results for its fourth quarter and year ended December 31, 2025. Fourth Quarter Highlights Net income available to common stockholders of $3.1 million and $55.6 million for the three months and year ended December 31, 2025, respectively, or $0.05 and $0.92 per diluted share, respectively.FFO of $0.47 and $2.00 per diluted share for the three months and year ended December 3...
American Assets Trust, Inc. Releases Tax Status of 2025 Distributions
American Assets Trust, Inc. Releases Tax Status of 2025 Distributions SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- American Assets Trust, Inc. (NYSE: AAT) (the “Company”) announced today the tax treatment of its 2025 dividend distributions as follows: Security Descriptions: Common StockCUSIP: 024013104Ticker Symbol: AAT Record DatePayable DateTotal Distribution Per ShareAllocable to 2025Taxable Ordinary DividendLT Capital GainUnrecaptured Sec. 1250 GainSection 199A DividendsReturn of Capital03/06/2503/20/25$0.340$0.340$0.140480$0.059651$0.042897$0.140480$0.13986906/05/2506/19/25$0.340$0....
American Assets Trust, Inc. Announces Fourth Quarter and Year-End 2025...
American Assets Trust, Inc. Announces Fourth Quarter and Year-End 2025 Earnings Release Date and Conference Call Information SAN DIEGO, Jan. 09, 2026 (GLOBE NEWSWIRE) -- American Assets Trust, Inc. (NYSE:AAT) (the “Company”) will announce its fourth quarter and year-end 2025 earnings in a press release to be issued after the market closes on Tuesday, February 3, 2026. Senior management will hold a conference call for its fourth quarter and year-end 2025 earnings on Wednesday, February 4, 2026 at 8:00 a.m. Pacific Time (“PT”). To access the conference call, please dial 1 (833) 816-1162 a...
- MarketLine Department
Builders FirstSource, Inc. - Mergers & Acquisitions (M&A), Partnership...
Summary Marketline's Builders FirstSource, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Builders FirstSource, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Allianc...
Avalo Therapeutics Announces Inducement Grants to New Employees Under ...
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) WAYNE, Pa., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the grant of inducement equity awards to three new employees. The Compensation Committee of the Board of Directors of Avalo approved the grants of nonstatutory stock options to purchase an aggregate of 114,000 shares of common stock (the “Options”) as indu...
- Jonathan Moreland
WWW WOLVERINE WORLD WIDE INC.
RGP RESOURCES CONNECTION INC.
NCLH NORWEGIAN CRUISE LINE HOLDINGS LTD.
MTDR MATADOR RESOURCES COMPANY
FTAI FORTRESS TRANSPORTATION AND INFRASTRUCTURE INVESTORS LLC
FLDM FLUIDIGM
FDS FACTSET RESEARCH SYSTEMS INC.
AROW ARROW FINANCIAL CORP.
GAM GENERAL AMERICAN INVESTORS CO. INC.
WHF WHITEFIELD
FMC FMC CORPORATION
LPX LOUISIANA-PACIFIC CORPORATION
SXC SUNCOKE ENERGY INC.
ITGR INTEGER HOLDINGS CORPORATION
ICHR ICHOR HOLDINGS LTD.
KREF KKR REAL ESTATE FINANCE TRUST
NWPP NEW PEOPLES BANKSHARES INC.
REZI RESIDEO TECHNOLOGIES
WU INC.
AEYE THE WESTERN UNION COMPANY
AMCR AUDIOEYE INC
BW AMCOR PLC
THRY BABCOCK & WILCOX ENTERPRISES
UTZ THRYV HOLDINGS
OPEN UTZ BRANDS INC (A)
ACVA OPENDOOR TECHNOLOGIES INC.
UPST ACV AUCTIONS INC.
FRSH UPSTART HOLDINGS
CLVT FRESHWORKS INC.
TRDA CLARIVATE PLC
SG ENTRADA THERAPEUTICS INC
TBBK SWEETGREEN INC
BLND THE BANCORP
CRVO INC.
NEXT ETRACS DJ-UBS COMMODITY INDEX 2-4-6 BLEND
SPRU CERVOMED INC
LAW NEXTSOURCE MATERIALS INC.
MRAI SPRUCE POWER HOLDING CORP
BNTC CS DISCO INC
GF MARPAI
HYMC INC.
SENS BENITEC BIOPHARMA INC
BATRK THE NEW GERMANY FUND
INC.
HYCROFT MINING HOLDING CORPORATION
SENSEONICS HOLDINGS INC.
LIBERTY MEDIA CORP
- Jonathan Moreland
BLMN BLOOMIN' BRANDS INC.
NCLH NORWEGIAN CRUISE LINE HOLDINGS LTD.
DLY LYONDELLBASELL INDUSTRIES NV
KMPR KEMPER CORPORATION
GOOD GLADSTONE COMMERCIAL CORPORATION
FLDM FLUIDIGM
CROX CROCS INC.
ASA ASA
AROW ARROW FINANCIAL CORP.
LPX LOUISIANA-PACIFIC CORPORATION
SXC SUNCOKE ENERGY INC.
TAP MOLSON COORS BEVERAGE COMPANY CLASS B
REZI RESIDEO TECHNOLOGIES
FSK INC.
WU FS KKR CAPITAL CORP
AEYE THE WESTERN UNION COMPANY
AMCR AUDIOEYE INC
AIMD.P AMCOR PLC
DKNG AIM4 VENTURES
OPEN DRAFTKINGS INC
ACVA OPENDOOR TECHNOLOGIES INC.
FRSH ACV AUCTIONS INC.
TRDA FRESHWORKS INC.
SG ENTRADA THERAPEUTICS INC
FRST SWEETGREEN INC
BLND PRIMIS FINANCIAL CORP
GTE ETRACS DJ-UBS COMMODITY INDEX 2-4-6 BLEND
LAW GRAN TIERRA ENERGY INC.
MRAI CS DISCO INC
GF MARPAI
RMI INC.
THE NEW GERMANY FUND
INC.
RIVERNORTH OPPOR MUN INC FD INC
- Dave Nicoski
- Ross LaDuke
Vermilion Short Shots: Technically Vulnerable Stocks
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
TGL. TECNOGLASS INC.
SM SM ENERGY COMPANY
MTDR MATADOR RESOURCES COMPANY
MDLZ MONDELEZ INTERNATIONAL INC. CLASS A
KAI KADANT INC.
JJSF J & J SNACK FOODS CORP.
HRL HORMEL FOODS CORPORATION
EEFT EURONET WORLDWIDE INC.
CVLT COMMVAULT SYSTEMS INC.
APOG APOGEE ENTERPRISES INC.
APD AIR PRODUCTS AND CHEMICALS INC.
ADP AUTOMATIC DATA PROCESSING INC.
WFT. WEST FRASER TIMBER CO. LTD.
NFLX NETFLIX INC.
HNI HNI CORPORATION
LPX LOUISIANA-PACIFIC CORPORATION
SXC SUNCOKE ENERGY INC.
TREX TREX COMPANY INC.
WSO WATSCO INC.
SPOT SPOTIFY TECHNOLOGY SA
MGY MAGNOLIA OIL & GAS CORP. CLASS A
CARR CARRIER GLOBAL CORP.
HPK HIGHPEAK ENERGY INC (A)
DFH DREAM FINDERS HOMES
FOUR SHIFT4 PAYMENTS
SRAD SPORTRADAR GROUP AG
2VZ LEONARDO DRS INC.
LIN LINDE PUBLIC LIMITED COMPANY
ETOR ETORO GROUP LTD
Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Re...
Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates Completed enrollment in Phase 2 LOTUS trial of AVTX-009 for the treatment of hidradenitis suppurativa; topline data expected mid-2026Appointed Kevin Lind to Board of DirectorsExpanded leadership team with key appointments in business development and human resourcesCash and short-term investments of approximately $112 million as of September 30, 2025 expected to provide runway into 2028 WAYNE, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechno...
Avalo Therapeutics to Participate in Upcoming Investor Conferences
Avalo Therapeutics to Participate in Upcoming Investor Conferences WAYNE, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced that management will participate in the following investor conferences: Guggenheim Second Annual Healthcare Innovation ConferenceFireside ChatNovember 10, 2025, at 4:00 pm ET Stifel 2025 Healthcare ConferenceFireside ChatNovember 12, 2025, at 2:40 pm ET TD Cowen 1st Immunology & Inflamm...
Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS...
Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa WAYNE, Pa., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced that the Company has completed enrollment in its Phase 2 LOTUS trial of AVTX-009 in adults with hidradenitis suppurativa (HS). The LOTUS trial exceeded target enrollment of 222 patients with approximately 250 patients enro...
American Assets Trust, Inc. Reports Third Quarter 2025 Financial Resul...
American Assets Trust, Inc. Reports Third Quarter 2025 Financial Results Net income available to common stockholders of $4.5 million and $52.5 million for the three and nine months ended September 30, 2025, respectively, or $0.07 and $0.87 per diluted share, respectively. Funds from Operations ("FFO") of $0.49 and $1.53 per diluted share for the three and nine months ended September 30, 2025, respectively. Increased 2025 FFO per diluted share guidance to a range of $1.93 to $2.01 with a midpoint of $1.97, a $0.02 increase over prior guidance. SAN DIEGO, Oct. 28, 2025 (GLOBE NEWSWIRE) ...
Avalo Therapeutics Expands Leadership Team with Key Appointments in Bu...
Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources WAYNE, Pa., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced the expansion of its leadership team with two senior appointments: Taylor Boyd has been named Chief Business Officer, and Ashley Ivanowicz has joined as Senior Vice President, Human Resources. “We are delighted to welcome Taylor and Ashley to Aval...
American Assets Trust, Inc. Announces Third Quarter 2025 Earnings Rele...
American Assets Trust, Inc. Announces Third Quarter 2025 Earnings Release Date and Conference Call Information SAN DIEGO, Sept. 30, 2025 (GLOBE NEWSWIRE) -- American Assets Trust, Inc. (NYSE:AAT) (the “Company”) will announce its third quarter 2025 earnings in a press release to be issued after the market closes on Tuesday, October 28, 2025. Senior management will hold a conference call for its third quarter 2025 earnings on Wednesday, October 29, 2025 at 8:00 a.m. Pacific Time (“PT”). To access the conference call, please dial 1 (833) 816-1162 and ask to join the American Assets Trust,...
Moody's Ratings announces completion of a periodic review of ratings o...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of Louisiana-Pacific Corporation and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 16 September 2025 in which we reassessed the appropriateness of the ratings i...
Avalo Therapeutics to Participate in Upcoming Investor Conferences
Avalo Therapeutics to Participate in Upcoming Investor Conferences WAYNE, Pa., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, today announced that management will participate in the following investor conferences: Cantor Global Healthcare ConferenceFireside ChatSeptember 3, 2025, at 2:10 pm ET H.C.Wainwright 27th Annual Global Investment ConferencePresentationSeptember 9, 2025, at 2:30 pm ET Stifel 2025 Virtual Immunology and...
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
Speculative Areas Still Leading; Staying Bullish We have discussed since late-July how the S&P 500 (SPX) had not closed below its 20-day MA for three months, but that even when it does, "all we would expect to happen is for a new, less-steep uptrend to form." That is precisely what has happened after the SPX finally lost its 20-day MA (for one whole day) on 8/1/25, only to get back to all-time highs last week. Therefore, we remain near-term bullish since our 4/22/25 Compass, and our intermediat...
INSM INSMED INCORPORATED
GPRE GREEN PLAINS INC.
CYTK CYTOKINETICS INCORPORATED
AXSM AXSOME THERAPEUTICS
ACAD ACADIA PHARMACEUTICALS INC.
REX REX AMERICAN RESOURCES CORPORATION
WVE WAVE LIFE SCIENCES
MRUS MERUS B V
BBIO BRIDGEBIO PHARMA
NVAX NOVAVAX INC.
RNA AVIDITY BIOSCIENCES
IREN IRIS ENERGY LTD
ACLX ARCELLX INC
APLD APPLIED BLOCKCHAIN INC
WGMI COINSHARES BITCOIN MINING ETF
KNSA KINIKSA PHARMACEUTICALS INTERNATIONAL PLC
HUT HUT 8 CORP
Avalo Reports Second Quarter 2025 Financial Results and Recent Busines...
Avalo Reports Second Quarter 2025 Financial Results and Recent Business Updates Topline data from Phase 2 LOTUS trial of AVTX-009 for the treatment of hidradenitis suppurativa expected mid-2026Rita Jain, M.D. appointed to Board of DirectorsCash and short-term investments of approximately $113 million as of June 30, 2025 expected to provide runway into 2028 WAYNE, Pa., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated inflammatory diseases, t...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.